Long-term data from a phase 3 study of radotinib versus imatinib in patients with newly diagnosed, chronic myeloid leukaemia in the chronic phase (RERISE)
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Do, Young Rok | - |
dc.contributor.author | Kwak, Jae-Yong | - |
dc.contributor.author | Kim, Jeong A. | - |
dc.contributor.author | Kim, Hyeoung Joon | - |
dc.contributor.author | Chung, Joo Seop | - |
dc.contributor.author | Shin, Ho-Jin | - |
dc.contributor.author | Kim, Sung-Hyun | - |
dc.contributor.author | Bunworasate, Udomsak | - |
dc.contributor.author | Choi, Chul Won | - |
dc.contributor.author | Zang, Dae Young | - |
dc.contributor.author | Oh, Suk Joong | - |
dc.contributor.author | Jootar, Saengsuree | - |
dc.contributor.author | Reksodiputro, Ary Harryanto | - |
dc.contributor.author | Lee, Won Sik | - |
dc.contributor.author | Mun, Yeung-Chul | - |
dc.contributor.author | Kong, Jee Hyun | - |
dc.contributor.author | Caguioa, Priscilla B. | - |
dc.contributor.author | Kim, Hawk | - |
dc.contributor.author | Park, Jinny | - |
dc.contributor.author | Kim, Dong-Wook | - |
dc.date.accessioned | 2021-08-31T04:39:50Z | - |
dc.date.available | 2021-08-31T04:39:50Z | - |
dc.date.created | 2021-06-19 | - |
dc.date.issued | 2020-04 | - |
dc.identifier.issn | 0007-1048 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/56714 | - |
dc.description.abstract | In the phase 3 study RERISE, patients with newly diagnosed chronic myeloid leukaemia in chronic phase demonstrated significantly faster and higher rates of major molecular response (MMR) with twice-daily radotinib 300 mg (n = 79) or 400 mg (n = 81) than with once-daily imatinib 400 mg (n = 81) after 12 months. With >= 48 months' follow-up, MMR was higher with radotinib 300 mg (86%) or 400 mg (83%) than with imatinib (75%). Among patients with BCR-ABL1 <= 10% at three months, MMR and molecular response 4 center dot 5 (MR4 center dot 5) were achieved within 48 months by more radotinib-treated patients (300 mg: 84% and 52%, respectively; 400 mg: 74% and 44%, respectively) than imatinib-treated patients (71% and 44%, respectively). Estimated overall and progression-free survival rates at 48 months were not significantly different between imatinib (94% and 94%, respectively) and radotinib 300 mg (99% and 97%, respectively) or 400 mg (95% and 93%, respectively). The treatment failure rate was significantly higher with imatinib (19%) than with radotinib 300 mg (6%; P = 0 center dot 0197) or 400 mg (5%; P = 0 center dot 0072). Safety profiles were consistent with previous reports; most adverse events occurred within 12 months. Radotinib continues to demonstrate robust, deep molecular responses, suggesting that treatment-free remission may be attainable. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | WILEY | - |
dc.subject | DASATINIB | - |
dc.subject | TRIAL | - |
dc.subject | DISCONTINUATION | - |
dc.subject | INHIBITOR | - |
dc.subject | NILOTINIB | - |
dc.subject | EFFICACY | - |
dc.subject | THERAPY | - |
dc.subject | SAFETY | - |
dc.title | Long-term data from a phase 3 study of radotinib versus imatinib in patients with newly diagnosed, chronic myeloid leukaemia in the chronic phase (RERISE) | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Choi, Chul Won | - |
dc.identifier.doi | 10.1111/bjh.16381 | - |
dc.identifier.scopusid | 2-s2.0-85078900629 | - |
dc.identifier.wosid | 000510537100001 | - |
dc.identifier.bibliographicCitation | BRITISH JOURNAL OF HAEMATOLOGY, v.189, no.2, pp.303 - 312 | - |
dc.relation.isPartOf | BRITISH JOURNAL OF HAEMATOLOGY | - |
dc.citation.title | BRITISH JOURNAL OF HAEMATOLOGY | - |
dc.citation.volume | 189 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 303 | - |
dc.citation.endPage | 312 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Hematology | - |
dc.relation.journalWebOfScienceCategory | Hematology | - |
dc.subject.keywordPlus | DASATINIB | - |
dc.subject.keywordPlus | TRIAL | - |
dc.subject.keywordPlus | DISCONTINUATION | - |
dc.subject.keywordPlus | INHIBITOR | - |
dc.subject.keywordPlus | NILOTINIB | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | SAFETY | - |
dc.subject.keywordAuthor | chronic myeloid leukaemia | - |
dc.subject.keywordAuthor | imatinib | - |
dc.subject.keywordAuthor | newly diagnosed | - |
dc.subject.keywordAuthor | long-term data | - |
dc.subject.keywordAuthor | radotinib | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.